Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy
Clinical Hematology International · 29.04.2024 · 6 (2)
DOI: 10.46989/001c.115932 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Hematology International, online erschienen am 29.04.2024. Verfasst von Nausheen Ahmed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor T-cell (CAR T-cell) therapy has changed the paradigm of management of non-Hodgkin’s lymphoma (NHL) and Multiple Myeloma. Infection complications have emerged as a concern that can arise in the setting of therapy and lead to morbidity and mortality. In this review, we classified infection complications into three categories, pre-infusion phase from the time pre- lymphodepletion (LD) up to day zero, early phase from day of infusion to day 30 post-infusion, and late phase after day 30 onwards. Infections arising in the pre-infusion phase are closely related to previous chemotherapy and bridging therapy. Infections arising in the early phase are more likely related to LD chemo and the expected brief period of grade 3-4 neutropenia. Infections arising in the late phase are particularly worrisome because they are associated with adverse risk features including prolonged neutropenia, dysregulation of humoral and adaptive immunity with lymphopenia, hypogammaglobinemia, and B cell aplasia. Bacterial, respiratory and other viral infections, protozoal and fungal infections can occur during this time . We recommend enhanced supportive care including prompt recognition and treatment of neutropenia with growth factor support, surveillance testing for specific viruses in the appropriate instance, management of hypogammaglobulinemia with repletion as appropriate and extended antimicrobial prophylaxis in those at higher risk (e.g. high dose steroid use and prolonged cytopenia). Finally, we recommend re-immunizing patients post CAR-T based on CDC and transplant guidelines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center.
- Medicine, Hematology and Oncology Vanderbilt University Medical Center.
Zitieren
APA
Ahmed, N., Oluwole, O., Mahmoudjafari, Z., Suleman, N., & McGuirk, J. P. (2024). Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy. Clinical Hematology International, 6(2). https://doi.org/10.46989/001c.115932
Vancouver
Ahmed N, Oluwole O, Mahmoudjafari Z, Suleman N, McGuirk JP. Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy. Clinical Hematology International. 2024;6(2). doi:10.46989/001c.115932
BibTeX
@article{Ahmed2024,
author = {Ahmed, Nausheen and Oluwole, Olalekan and Mahmoudjafari, Zahra and Suleman, Nahid and McGuirk, Joseph P},
title = {Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy},
journal = {Clinical Hematology International},
year = {2024},
volume = {6},
number = {2},
doi = {10.46989/001c.115932}
}
EUVIMED